MAIA Biotechnology Inc
Research MAIA Biotechnology Inc (MAIA) on Bullrun: market cap USD 71.76M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerMAIA
- ExchangeNYSE MKT
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 71.76M
- Financial periodQ2 2026
- RevenueUSD 0
- Net income-USD 7.94M
- Free cash flow-USD 6.75M
Valuation Snapshot
latest market cap is USD 71.76M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 22.40M | -USD 18.84M | n/a | -0.7 | USD 0 | n/a | USD 2.38M |
| FY2024 | USD 0 | -USD 23.25M | -USD 15.70M | n/a | -1.05 | USD 0 | n/a | USD 3.63M |
| FY2023 | USD 0 | -USD 19.77M | -USD 13.07M | n/a | -1.49 | USD 0 | n/a | USD 477.51K |
| FY2022 | USD 0 | -USD 15.77M | -USD 12.10M | n/a | -1.75 | USD 0 | USD 0 | USD 8.51M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-12 | USD 71.76M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 59.10M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 51.79M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 19.85M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 38.42M | n/a | n/a | n/a |
About MAIA Biotechnology Inc
MAIA Biotechnology, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the development of targeted immunotherapies for cancer. Its lead product Ateganosine, a telomere-targeting agent currently in clinical development to evaluate its activity in Non-Small Cell Lung Cancer (NSCLC). The company was incorporated in 2018 and is headquartered in Chicago, Illinois.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is MAIA Biotechnology Inc's market cap?
MAIA Biotechnology Inc's market capitalization is USD 71.76M.
What does MAIA Biotechnology Inc do?
MAIA Biotechnology, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the development of targeted immunotherapies for cancer. Its lead product Ateganosine, a telomere-targeting agent currently in clinical development to evaluate its activity in Non-Small Cell Lung Cancer (NSCLC). The company was incorporated in 2018 and is headquartered in Chicago, Illinois.